These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 34119558)

  • 41. Recent advances and strategies for nanocarrier-mediated topical therapy and theranostic for posterior eye disease.
    Faria MJ; González-Méijome JM; Real Oliveira MECD; Carracedo G; Lúcio M
    Adv Drug Deliv Rev; 2024 Jul; 210():115321. PubMed ID: 38679293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nanoparticles for ocular drug delivery: modified and non-modified chitosan as a promising biocompatible carrier.
    Pontillo ARN; Detsi A
    Nanomedicine (Lond); 2019 Jul; 14(14):1889-1909. PubMed ID: 31274373
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye.
    Loftsson T; Stefánsson E
    Int J Pharm; 2017 Oct; 531(2):413-423. PubMed ID: 28391041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent patents on ocular drug delivery systems.
    Conway BR
    Recent Pat Drug Deliv Formul; 2008; 2(1):1-8. PubMed ID: 19075892
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cell penetrating peptides in ocular drug delivery: State of the art.
    Pescina S; Ostacolo C; Gomez-Monterrey IM; Sala M; Bertamino A; Sonvico F; Padula C; Santi P; Bianchera A; Nicoli S
    J Control Release; 2018 Aug; 284():84-102. PubMed ID: 29913221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Delivery of therapeutics for deep-seated ocular conditions - status quo.
    Nguyen H; Eng S; Ngo T; Dass CR
    J Pharm Pharmacol; 2018 Aug; 70(8):994-1001. PubMed ID: 29675844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Topical delivery of ocular therapeutics: carrier systems and physical methods.
    Souza JG; Dias K; Pereira TA; Bernardi DS; Lopez RF
    J Pharm Pharmacol; 2014 Apr; 66(4):507-30. PubMed ID: 24635555
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Controlled and continuous release ocular drug delivery systems: pros and cons.
    Abdelkader H; Alany RG
    Curr Drug Deliv; 2012 Jul; 9(4):421-30. PubMed ID: 22640036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel drug delivery systems for ocular therapy: With special reference to liposomal ocular delivery.
    Bhattacharjee A; Das PJ; Adhikari P; Marbaniang D; Pal P; Ray S; Mazumder B
    Eur J Ophthalmol; 2019 Jan; 29(1):113-126. PubMed ID: 29756507
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patent perspectives for corticosteroids based ophthalmic therapeutics.
    Suresh PK; Sah AK
    Recent Pat Drug Deliv Formul; 2014; 8(3):206-23. PubMed ID: 25020063
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery.
    Shen HH; Chan EC; Lee JH; Bee YS; Lin TW; Dusting GJ; Liu GS
    Nanomedicine (Lond); 2015; 10(13):2093-107. PubMed ID: 26096379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage.
    Liu S; Dozois MD; Chang CN; Ahmad A; Ng DL; Hileeto D; Liang H; Reyad MM; Boyd S; Jones LW; Gu FX
    Mol Pharm; 2016 Sep; 13(9):2897-905. PubMed ID: 27482595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nanocarriers in ocular drug delivery: an update review.
    Wadhwa S; Paliwal R; Paliwal SR; Vyas SP
    Curr Pharm Des; 2009; 15(23):2724-50. PubMed ID: 19689343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distribution of polymeric nanoparticles in the eye: implications in ocular disease therapy.
    Swetledge S; Jung JP; Carter R; Sabliov C
    J Nanobiotechnology; 2021 Jan; 19(1):10. PubMed ID: 33413421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A review of topically administered mini-tablets for drug delivery to the anterior segment of the eye.
    Moosa RM; Choonara YE; du Toit LC; Kumar P; Carmichael T; Tomar LK; Tyagi C; Pillay V
    J Pharm Pharmacol; 2014 Apr; 66(4):490-506. PubMed ID: 24635554
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nanotherapies for the treatment of ocular diseases.
    Reimondez-Troitiño S; Csaba N; Alonso MJ; de la Fuente M
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):279-93. PubMed ID: 25725262
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nanotherapy for posterior eye diseases.
    Kaur IP; Kakkar S
    J Control Release; 2014 Nov; 193():100-12. PubMed ID: 24862316
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond.
    Destruel PL; Zeng N; Maury M; Mignet N; Boudy V
    Drug Discov Today; 2017 Apr; 22(4):638-651. PubMed ID: 28017837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions.
    Suresh PK; Sah AK
    Expert Opin Drug Deliv; 2014 Nov; 11(11):1747-68. PubMed ID: 25007007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-invasive strategies for targeting the posterior segment of eye.
    Madni A; Rahem MA; Tahir N; Sarfraz M; Jabar A; Rehman M; Kashif PM; Badshah SF; Khan KU; Santos HA
    Int J Pharm; 2017 Sep; 530(1-2):326-345. PubMed ID: 28755994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.